Prognostic role of PD-L1 expression in patients with advanced renal cell carcinoma (RCC) treated with sunitinib.

603Background: the prognosis and treatment of advanced RCC has improved over the last decade due to a number of effective anti-angiogenic and immune checkpoint inhibitors (ICPI) therapies. Certain clinical factors, such as low Karnofsky status (≤ 70%); less than a one year period from diagnosis to treatment administration; low serum hemoglobin; high corrected serum calcium; high lactate dehydrogenase; elevated neutrophil count or platelet count exceeding the upper limit of the normal range, have been able to stratify patients into three distinct prognostic groups: favorable (zero risk factors), intermediate (one to two), and poor risk (more than two). Nowadays, the relationship between PD-L1 expression with treatment response and the survival rate of RCC is a current topic of interest. Methods: a retrospective analysis of 182 patients with advanced RCC who received sunitinb in a single Institution has been conducted with the aim of analyzing PD-L1 as a prognostic factor. To carry out the immunohistochemic...